Fairman Jeff
SEC CIK 1813800 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| PCVX | Vaxcyte, Inc. | VP, Research | 286.2K | — | $2.23M | 25 | 2021-07-26 | 2022-10-26 |
Most active insiders at PCVX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | PICKERING GRANT | CEO, Dir | — | $3.63M |
| 2 | GUGGENHIME ANDREW | Pres AND CFO | — | $1.64M |
| 3 | Wassil Jim | EVP, COO, Chief Scientific Ofc | — | $1.43M |
| 4 | Dhaliwal Harpreet S. | Chief Technical Ops Off | — | $1.39M |
| 5 | Cowan Elvia | SVP, Fin | — | $988.6K |
| 6 | Jodar Luis | Chief Medical Off | — | — |
| 7 | Lee Jacks | Dir | — | — |
| 8 | Loxam Teri | Dir | — | — |
| 9 | Furey John | Dir | — | — |
| 10 | Paya Carlos V | Dir | — | — |
Fairman Jeff made no open-market trades at PCVX in the last 12 months.
Transactions 25
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2022-10-28 | 2022-10-26 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | S - Sale | $40.00 | -10.0K | 286.2K | -3% | -$400.0K |
| I | 2022-10-13 | 2022-10-11 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | S - Sale | $25.50 | -5,000 | 296.2K | -2% | -$127.5K |
| 2022-09-07 | 2022-09-02 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | F - Tax | $26.38 | -519 | 17.1K | -3% | -$13.7K | |
| MI | 2022-09-07 | 2022-09-06 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | S - Sale | $26.58 | -5,000 | 301.2K | -2% | -$132.9K |
| MI | 2022-08-05 | 2022-08-04+ | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | S - Sale | $25.57 | -15.0K | 306.2K | -5% | -$383.5K |
| I | 2022-05-24 | 2022-05-20 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | S - Sale | $25.50 | -4,112 | 321.2K | -1% | -$104.9K |
| I | 2022-05-09 | 2022-05-05 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | S - Sale | $25.80 | -888 | 325.3K | -0.3% | -$22.9K |
| I | 2022-04-07 | 2022-04-05 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | S - Sale | $25.59 | -5,000 | 326.2K | -2% | -$128.0K |
| I | 2022-03-15 | 2022-03-11 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | S - Sale | $25.50 | -10.0K | 331.2K | -3% | -$255.0K |
| D | 2022-03-04 | 2022-03-02 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | A - Grant | $0.00 | +6,000 | 16.6K | +56% | $0 |
| D | 2022-02-08 | 2021-12-20 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | M - OptEx | $1.79 | +4,469 | 10.6K | +73% | +$8,000 |
| DM | 2021-12-28 | 2021-12-27 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | S - Sale+OE | $23.60 | -4,750 | 6,335 | -43% | -$112.1K |
| D | 2021-12-28 | 2021-12-27 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | M - OptEx | $1.79 | +4,750 | 10.9K | +77% | +$8,502 |
| D | 2021-12-20 | 2021-12-16 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | M - OptEx | $1.79 | +4,619 | 10.8K | +75% | +$8,268 |
| D | 2021-12-20 | 2021-12-16 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | S - Sale+OE | $22.50 | -4,619 | 6,160 | -43% | -$103.9K |
| D | 2021-12-13 | 2021-12-09 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | S - Sale+OE | $22.50 | -131 | 6,160 | -2% | -$2,948 |
| D | 2021-12-13 | 2021-12-09 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | M - OptEx | $1.79 | +131 | 6,291 | +2% | +$234.49 |
| D | 2021-10-28 | 2021-10-26 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | M - OptEx | $1.79 | +4,750 | 9,894 | +92% | +$8,502 |
| D | 2021-10-28 | 2021-10-26 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | S - Sale+OE | $22.69 | -4,750 | 5,144 | -48% | -$107.8K |
| DM | 2021-09-29 | 2021-09-27 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | S - Sale+OE | $26.17 | -4,750 | 5,283 | -47% | -$124.3K |
| D | 2021-09-29 | 2021-09-27 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | M - OptEx | $1.79 | +4,750 | 9,894 | +92% | +$8,502 |
| D | 2021-08-30 | 2021-08-26 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | M - OptEx | $1.79 | +4,750 | 9,894 | +92% | +$8,502 |
| DM | 2021-08-30 | 2021-08-26 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | S - Sale+OE | $25.38 | -4,750 | 8,362 | -36% | -$120.5K |
| D | 2021-07-28 | 2021-07-26 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | S - Sale+OE | $22.70 | -4,750 | 5,144 | -48% | -$107.8K |
| D | 2021-07-28 | 2021-07-26 | PCVX | Vaxcyte, Inc. | Fairman Jeff | VP, Research | M - OptEx | $1.79 | +4,750 | 9,894 | +92% | +$8,502 |
Purchase Sale Sale after option exercise All abbreviations